Acumen Pharmaceuticals, Inc. (ABOS)
ABOS has a market cap or net worth of $140.94 million. The enterprise value is -$47.94 million.
The next earnings date is Monday, June 27, 2022, before market open.
|Estimated Earnings Date||Jun 27, 2022|
ABOS has 40.50 million shares outstanding. The number of shares has increased by 9,556.63% in one year.
|Shares Change (YoY)||+9,556.63%|
|Shares Change (QoQ)||+101.79%|
|Owned by Insiders (%)||15.73%|
|Owned by Institutions (%)||77.93%|
|EV / Earnings||n/a|
|EV / Sales||n/a|
|EV / EBITDA||n/a|
|EV / EBIT||n/a|
|EV / FCF||n/a|
The company has a current ratio of 48.81, with a Debt / Equity ratio of 0.00.
|Debt / Equity||0.00|
|Debt / EBITDA||n/a|
|Debt / FCF||n/a|
Return on equity (ROE) is -58.20%, which is considered low. The company has a ROIC of -107.50%.
|Return on Equity (ROE)||-58.20%|
|Return on Assets (ROA)||-43.60%|
|Return on Capital (ROIC)||-107.50%|
|Revenue Per Employee||n/a|
|Profits Per Employee||-$5.91M|
|Effective Tax Rate||n/a|
Stock Price Statistics
|Total Price Change||-78.25%|
|50-Day Moving Average||3.78|
|200-Day Moving Average||6.13|
|Average Volume (30 Days)||232,119|
Short Selling Information
The latest short interest is 1.90 million, so 4.68% of the outstanding shares have been sold short.
|Short % of Shares Out||4.68%|
|Short % of Float||13.36%|
|Short Ratio (days to cover)||9.26|
|Earnings Per Share (EPS)||-$2.75|
The company has $189.09 million in cash and $201,000 in debt, giving a net cash position of $188.89 million or $4.66 per share.
|Cash & Cash Equivalents||189.09M|
|Net Cash Per Share||$4.66|
|Book Value Per Share||5.34|
In the last 12 months, operating cash flow was -$23.89 million and capital expenditures -$43,000, giving a free cash flow of -$23.93 million.
|Operating Cash Flow||-23.89M|
|Free Cash Flow||-23.93M|
|FCF Per Share||n/a|
Dividends & Yields
ABOS does not appear to pay any dividends at this time.
|Dividend Per Share||n/a|
|Dividend Growth (YoY)||n/a|
The average price target for ABOS is $17.85, which is 412.93% higher than the current price. The consensus rating is "Buy".
|Price Target Difference||412.93%|
This stock does not have any record of stock splits.
|Last Split Date||n/a|